AOD-9604: Uses, Benefits & Research

What is AOD-9604?

AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminus of human growth hormone (hGH), specifically residues 177-191. Its amino acid sequence is Gly-Leu-Ser-Asn-Asp-Met-Ser-Asp-Arg-Phe-Leu-Gln-Lys-Gly-Leu, with a molecular weight of approximately 2,012 Da. The fragment was designed to isolate the “lipolytic domain” of growth hormone — the portion responsible for fat metabolism — without the growth-promoting and diabetogenic effects of full-length GH.

Originally developed by Novo Nordisk, AOD-9604 was granted GRAS (Generally Recognized as Safe) status in 2003 but later withdrew from FDA review after its pivotal clinical trial failed to demonstrate statistically significant weight loss.

Mechanism of Action

AOD-9604 binds to GH receptors but activates a different intracellular signaling cascade than full-length growth hormone. Specifically, it triggers the lipolytic pathway (fat breakdown) without significantly elevating IGF-1. This selective activation was the theoretical advantage over using actual growth hormone for fat loss — the fat-metabolizing benefits without the insulin resistance, edema, and growth effects.

In preclinical models, AOD-9604 has been shown to:

• Stimulate lipolysis (breakdown of stored fat)
• Inhibit lipogenesis (formation of new fat)
• Improve lipid profiles in obese rodent models
• Act independently of the IGF-1 axis

All mechanistic data is from animal and in vitro studies. No direct human pharmacodynamic studies have characterized the mechanism in people.

Clinical Evidence

Human Studies

AOD-9604 has more completed human clinical trial data than most peptides, with 6 trials enrolling over 900 participants:

Study	Type	Participants	Key Finding
Phase I safety	RCT	~100	Safe and well-tolerated
Phase IIa	RCT	~200	2.6 kg weight loss at 12 weeks (1mg/day)
Phase IIb (pivotal)	RCT	~300	Failed to meet primary endpoint
23-week study	RCT	~300	2.8 kg vs 0.8 kg placebo

The critical finding: the largest, most rigorous Phase IIb trial failed to achieve statistical significance for the primary weight loss endpoint. This is why Novo Nordisk discontinued development.

Preclinical Evidence

Model	Species	Finding
Obese Zucker rat	Rat	Reduced body weight, improved lipids
ob/ob mouse	Mouse	Fat mass reduction
Diet-induced obesity	Rat	Prevented weight gain
Lipolysis assay	Rat adipocytes	Direct lipolytic effect

Drug Interactions & Contraindications

No formal drug interaction studies have been conducted. Theoretical interactions exist with weight loss medications (additive effects), thyroid medications, insulin/diabetes drugs, and corticosteroids. Contraindicated in pregnancy, active malignancy, and concurrent growth hormone therapy.

Safety & Side Effects

AOD-9604 was consistently safe and well-tolerated across all 6 clinical trials (900+ participants). No serious adverse events were attributed to treatment. Common side effects included injection site reactions (~10%), headache (~5-8%), nausea (~3-5%), and fatigue (~3-5%). This is actually one of the better safety profiles among peptides with human data.

Theoretical concerns include cancer risk (GH/IGF-1 pathway), diabetes risk, and antibody formation — none of which were observed in trials.

Honest Bottom Line

AOD-9604 presents a complicated picture. It has more completed human clinical trials than almost any other peptide in this space, and early Phase II data showed promising weight loss signals. The safety profile was consistently good.

However, the pivotal Phase IIb trial failed its primary endpoint, which is why development was discontinued. In the era of GLP-1 receptor agonists (semaglutide, tirzepatide) demonstrating 15-20%+ weight loss, AOD-9604’s modest 2-3 kg effect seems trivial by comparison.

Patients considering AOD-9604 should understand: this compound was rigorously studied and failed its definitive trial. It is not FDA-approved for a reason. The “completed clinical trials” narrative should be viewed in context of a discontinued development program.